Analysis of biochemical changes in muscular tissue of rats with hypercholesterolemia combined introduction of simvastatin and coenzym Q10


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Introduction. Statins are a group of effective lipid - lowering medications. A common side effect of long-term statin use is myopathy. The mechanism of its development is not fully understood at the molecular level, making it difficult to find effective drugs preventing and correcting muscle damage. According to one hypothesis, the pathogenesis of statin myopathy is based on CoQ deficiency. The aim of the study. To analyze metabolic changes in the muscle tissue in rats with essential hypercholesterolemia when simvastatin and coenzyme were co-administered. Methods. 120 male rats were divided into two groups: the first group was kept on a vivarium diet, and the second group was administered essential hypercholesterolemia. Animals of the experimental group were divided into subgroups: 1 - on a diet without drug administration; 2 - simvastatin, 3 - simvastatin and CoQ10 At the end of the experiment, the concentrations of pyruvic acid, lactic acid, and reduced glutathione, the activity of glutathione reductase, glutathione peroxidase, and succinate dehydrogenase and cytochrome oxidase were determined in animal muscles. Results. In the muscles of animals with hypercholesterolemia, the introduction of simvastatin promotes the transition to anaerobic oxidation. The administration of simvastatin to animals with hypercholesterolemia was shown to induce a depression of the glutathione-dependent link of antioxidant protection and inhibition of respiratory chain enzymes at the level of cytochrome oxidase and succinate dehydrogenase. Against the background of coenzyme administration, multidirectional changes in lactate and pyruvate are registered in favor of the growth of the latter. The level of reduced glutathione tends to decrease compared to the group receiving simvastatin. The activity of glutathione reductase has not changed, and glutathione peroxidase corresponds to the indices of rats with hypercholesterolemia. The activity of succinate dehydrogenase and cytochrome oxidase is recorded at the level of control values. Conclusion. Combined administration of simvastatin and coenzyme is effective for optimizing the mitochondrial respiratory chain, which can be recommended for clinical studies to evaluate the effectiveness of including coenzyme Q10 in complex therapy of myopathy.

全文:

受限制的访问

作者简介

Zoya Mikashinovich

Rostov State Medical University

Email: mikashinovich@gmail.com
head of the department general and clinical biochemistry №1

Inna Semenets

Rostov State Medical University

Email: semenets.i.a@mail.ru
post-graduate student, department of general and clinical biochemistry №1

参考

  1. Schuster H. The GALAXY Program an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Investigating cardiovascular risk reduction - the Rosuvastatin GALAXY Programme. Expert Rev. Cardiovasc. Ther. 2007; 5: 177-93. D0l:10.1586/14779072.5.2.177.
  2. Sever PS., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kristinsson A., Mehlsen J., Nieminen M., O'Brien E., Ostergren J., ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet. 2003; 361: 1149-58. DOI:10.1016/ S0140-6736(03)12948-0.
  3. Долженко М.Н., Базилевич А.Я., Симагина Т.В., Конопляник Л.И. Безопасность статинов: за и против. Мистецтво лмкування. 2010; 2 (68): 26-34.
  4. Evans M., Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf. 2002; 25 (9): 649-63. doi: 10.2165/00002018-200225090 00004.
  5. Sewright K.A., Clarkson P.M., Thompson P.D. Statin myopathy: incidence, risk factors, and pathophysiology Curr Atheroscler Rep. 2007; 9 (5): 389-96. DOI: 10.1007/ s11883-007-0050-3.
  6. Arora R., Liebo M., Maldonado F. Statin-induced myopathy: the two faces of Janus. J. Cardiovasc Pharmacol Ther. 2006; 11 (2): 105-12. doi: 10.1177/1074248406288758.
  7. Meador B.M., Huey K.A. Statin-associated myopathy and its exacerbation with exercise. Muscle Nerve. 2010; 42 (4): 469-79. doi: 10.1002/mus.21817.
  8. Dirks A.J., Jones K.M. Statin-induced apop-tosis and skeletal myopathy. Am. J. Physiol. Cell. Physiol. 2006; 291 (6): 1208-12. doi: 10.1152/ajpcell.00226.2006.
  9. Toth P.P., Harper C.R., Jacobson T.A. Clinical characterization and molecular mechanisms of statin myopathy Expert Rev Cardiovasc Ther. 2008; 6 (7): 955-69. doi: 10.1586/14779072.6.7.955.
  10. Caso G., Kelly P., McNurlan M.A., Lawson W.E. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am. J. Cardiol. 2007; 99: 1409-12; doi: 10.1016/j.amjcard.2006.12.063.
  11. Драпкина О.М., Чернова Е.М., Корнеева О.Н. Статины и миопатия: молекулярные механизмы. Рациональная фармакотерапия в кардиологии. 2012; 8 (3): 469-73.
  12. Taylor B.A., Lorson L., White C.M., Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy Atherosclerosis. 2015; 238: 329-35. doi: 10.1016/j.atherosclerosis.2014.12.016.
  13. Banach M., Serban C., Sahebkar A., Ursoniu S., Rysz J., Muntner P., Toth P.P., Jones S.R., Rizzo M., Glasser S.P., Lip G.Y., Dragan S., Mikhailidis D.P. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015; 90: 24-34. DOI: 10.1016/j. mayocp.2014.08.021.
  14. Skarlovnik A., Janie M., Lunder M., Turk M., Sabovic M. Coenzyme Q10 supplementation decreases statin-related mild-to-mod-erate muscle symptoms: a randomized clinical study Med Sci Monit. 2014; 20: 2183-8. doi: 10.12659/MSM.890777.
  15. Qu H., Guo M., Chai H., Wang W.T., Gao Z.Y., Shi D.Z. Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials. J. Am. Heart Assoc. 2018; 7: e009835. doi: 10.1161/jaha.118.009835.
  16. Патент РФ на изобретение №2020111021/16.03.20., Микашинович З.И., Белоусова Е.С., Семенец И.А., Ромашенко А.В., Кантария А.В. Способ моделирования эссенциальной гиперхолестеринемии. Опубликовано: 06.10.2020. Бюл. № 28. Ссылка активна на 16.10.2020.
  17. Справочник по лабораторным методам исследований. Под ред. Л.А. Даниловой. Издательский Дом ПИТЕР, 2003.
  18. Микашинович З.И., Летуновский А.В., Волжин О.О., Белоусова Е.С. Биохимические исследования слюны в клинической практике. М.: Издательство РостГМУ (Ростов-на-Дону), 2004.
  19. Микашинович З.И., Белоусова Е.С., Виноградова Е.В., Семенец И.А. Ферментативная антиоксидантная защита в мышцах крыс при длительном введении симвастатина. Медицинский вестник Башкортостана. 2017; 12.1 (67): 54-7.
  20. Калинина Е.В., Чернов Н.Н., Алеид Р., Новичкова М.Д., Саприн А.Н., Березов ТТ Современные представления об антиоксидантной роли глутатиона и глутатионзависимых ферментов. Вестник РАМН. 2010; 3: 46-54.
  21. Ланкин В.З., Тихазе А.К., Беленков Ю.Н. Антиоксиданты в комплексной терапии атеросклероза: pro et contra. Кардиология. 2004; 2: 70 - 81.

补充文件

附件文件
动作
1. JATS XML

版权所有 © Russkiy Vrach Publishing House, 2021
##common.cookie##